Patient P-01668

Synthetic patientNBL-101 · Day 117 · 45–54 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Unstable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

80%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 55 GI-04 recommended — GI Support Protocol GI-04
Day 56 Patient accepted — Started GI-04 in the companion
Day 64 No meaningful change — GI Support Protocol GI-04
Day 64 ME-01 recommended — Monitoring Escalation ME-01
Day 65 Patient accepted — Started ME-01 in the companion
Day 68 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

Inflammatory activity-11
Nutritional resilience-8
Toxicity-6
GI instability+3

What helped?

GI Support Protocol GI-04Day 55
Result: no meaningful change
Monitoring Escalation ME-01Day 64
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

57%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

67.2/100

worsening · +3.5 vs previous 14 d

Toxicity

Blood

47.2/100

worsening · +2.2 vs previous 14 d

Sleep quality

Wearable

36.6/100

improving · +1.7 vs previous 14 d

Energy level

Daily log

2.9/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

5.8/10

stable · +0.2 vs previous 14 d

Steps

Wearable

5,190

stable · -59 vs previous 14 d

Adherence

Companion

46.2 %

improving · +6.5 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 36 from the failing basin, 64 from restoration.

Would help

NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 69%
SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 69%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 69%

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep histamine low
GI +4.5 next day on high-intake days · n 18
Keep fat low
GI +2.9 next day on high-intake days · n 23
Keep fibre low
GI +2.7 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+4.5detractor · 95%
Dietary fat load
+2.9detractor · 95%
Insoluble fibre
+2.7detractor · 87%
Simple carbohydrates
+2.5detractor · 78%
Spicy / capsaicin
-1.8no signal · 52%
Alcohol
-1no signal · 28%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 67 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
Drug metabolism and exposure ↑20
- BloodToxicity index 47
Autonomic recovery ↓20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 37/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 51 ms
Sleep: 6.4 h
Steps: 3,996
Resting HR: 68 bpm

Daily log: GI score 67, nutritional resilience 31, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01327	36%	S01	GI-04	improved	56
P-01813	35%	S01	NP-02	no change	40
P-01310	32%	S01	—	—	57
P-01688	29%	S01	GI-04	improved	40
P-01877	28%	S01	CR-01	improved	67
P-01604	20%	S01	—	—	71
P-01821	20%	S01	—	—	58
P-01823	20%	S01	—	—	57
P-01635	35%	S02	GI-04	improved	49
P-01452	32%	S02	GI-04	improved	46
P-01459	30%	S02	—	—	51
P-01498	20%	S02	—	—	56